
Please try another search
NEW HAVEN - The U.S. Food and Drug Administration has accepted the New Drug Application for vepdegestrant, an investigational treatment for patients with estrogen receptor-positive, HER2-negative,...
Investing.com - Morgan Stanley (NYSE:MS) has raised its price target on Pfizer (NYSE:PFE) stock to $33.00 from $32.00 while maintaining an Equalweight rating on the pharmaceutical giant....
Investing.com -- The S&P 500 closed lower Tuesday after data showing services activity unexpectedly contracted stoked concerns about the underlying of the economy just as the quarterly earnings season...
Introduction & Market Context Pfizer Inc. (NYSE:PFE) presented its second quarter 2025 earnings results on August 5, showcasing strong financial performance that exceeded analyst expectations. The...
Pfizer Inc. reported stronger-than-expected earnings for the second quarter of 2025, with both revenue and earnings per share (EPS) surpassing analyst forecasts. The pharmaceutical giant posted an EPS...
Investing.com -- U.S. stocks fell sharply on Friday as markets opened August with renewed concerns about economic weakness and the impact of newly adjusted tariffs announced by President Donald...
Investing.com -- Pfizer (NYSE:PFE) and its German partner BioNTech (NASDAQ:BNTX) failed to overturn a ruling that their COVID-19 vaccine infringed one of Moderna 's (NASDAQ:MRNA) patents,...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review